Here’s the thing about 9.00 that catches most people off guard: diabetes itself doesn’t have its own sub-listing. Neither do most other endocrine disorders. SSA evaluates endocrine conditions by their effects on OTHER body systems — and most endocrine SSDI claims actually qualify under those other listings rather than 9.00 directly.
How 9.00 actually works
The endocrine section of the Blue Book is unusual because it functions primarily as a cross-reference to other categories. The introduction explicitly directs adjudicators to evaluate endocrine conditions by their downstream effects:
- Diabetes with neuropathy → evaluated under 11.14 (Peripheral neuropathy)
- Diabetic retinopathy → evaluated under 2.00 (Special Senses)
- Diabetic nephropathy → evaluated under 6.00 (Genitourinary)
- Diabetic cardiovascular disease → evaluated under 4.00 (Cardiovascular)
- Diabetic foot complications requiring amputation → evaluated under 1.20 (Amputation)
- Thyroid disease causing arrhythmia → evaluated under 4.05
- Adrenal disease causing osteoporosis with fractures → evaluated under 1.19
- Pituitary disorders affecting growth in children → evaluated under 100.00s (Part B)
What this means for your case
If you have diabetes and you’re trying to qualify for SSDI, the question isn’t “does my diabetes meet a listing?” The question is: “what complications has my diabetes caused, and do any of those complications meet a listing?”
A claimant with type 1 diabetes who has stable A1c on insulin probably doesn’t meet ANY listing — but a claimant with type 1 diabetes who has documented peripheral neuropathy with sustained motor and sensory loss in both feet may meet 11.14, AND have additional diabetic retinopathy that approaches 2.00 visual criteria, AND have early-stage CKD that’s heading toward 6.05.
The strongest endocrine cases
In practice, the endocrine cases that most clearly win involve multiple complications:
- Type 1 or advanced type 2 diabetes with peripheral neuropathy + retinopathy + nephropathy (often combined approaches multiple listings)
- Thyroid storm or myxedema coma with persistent residual deficits
- Pituitary disorders with severe panhypopituitarism
- Adrenal insufficiency (Addison’s disease) with crisis episodes requiring hospitalization
The medical-vocational path
For endocrine claimants who don’t meet a downstream listing, the case usually shifts to residual functional capacity (RFC). The argument: “my diabetes with neuropathy and frequent hypoglycemia events means I can’t reliably perform any 8-hour workday.”
Documentation that strengthens an RFC argument for endocrine claimants: glucose log showing significant variability, hypoglycemia events requiring assistance, hospitalizations for DKA or hyperglycemic emergencies, foot ulcer history, neuropathy symptoms documented in chart notes, fatigue patterns from poor metabolic control.
What evidence wins endocrine cases
Endocrinologist treatment records spanning 12+ months. Recent A1c values (multiple measurements over time). Comprehensive labs (CMP, lipid panel, thyroid function as relevant). Documentation of complications by relevant specialists (neurologist for neuropathy, ophthalmologist for retinopathy, nephrologist for renal involvement).
Where these cases fall apart
The most common pattern: claimants present diabetes as the disabling condition, but the case lacks documentation of specific complications meeting other listings. SSA reads the file as “diabetes managed on insulin, A1c around 8, no documented complications” — and denies on the basis that controlled diabetes isn’t disabling.
The fix: be specific about complications. Don’t claim diabetes; claim “diabetic peripheral neuropathy with documented loss of sensation in both lower extremities, plus diabetic retinopathy with visual acuity of 20/100, plus stage 3 CKD with eGFR 35.” Each complication is a separate argument.
Free consultation
If you have diabetes with significant complications, advanced thyroid or adrenal disease, or pituitary disorders, a free 30-minute call helps identify which downstream listings your case most cleanly fits — and what evidence we’d need to develop for each.
Official SSA reference: View Section 9.00 on ssa.gov →